NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 124 filers reported holding NGM BIOPHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,123,240 | +9.8% | 1,984,336 | +165.8% | 0.23% | -53.3% |
| Q2 2023 | $1,933,886 | -36.5% | 746,674 | 0.0% | 0.50% | -81.4% |
| Q1 2023 | $3,046,430 | -18.7% | 746,674 | 0.0% | 2.67% | -23.8% |
| Q4 2022 | $3,748,303 | -61.6% | 746,674 | 0.0% | 3.51% | -61.3% |
| Q3 2022 | $9,766,000 | +2.0% | 746,674 | 0.0% | 9.07% | +11.4% |
| Q2 2022 | $9,572,000 | -15.9% | 746,674 | 0.0% | 8.14% | +23.0% |
| Q1 2022 | $11,387,000 | -13.9% | 746,674 | 0.0% | 6.62% | -12.0% |
| Q4 2021 | $13,224,000 | -24.4% | 746,674 | -10.3% | 7.52% | -11.6% |
| Q3 2021 | $17,494,000 | -40.6% | 832,274 | -44.3% | 8.50% | -11.0% |
| Q2 2021 | $29,449,000 | -32.2% | 1,493,349 | 0.0% | 9.56% | -34.2% |
| Q1 2021 | $43,412,000 | -31.2% | 1,493,349 | -28.3% | 14.52% | +8.7% |
| Q4 2020 | $63,133,000 | – | 2,083,602 | – | 13.36% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $59,928,000 | 49.90% |
| Greenspring Associates, LLC | 1,573,357 | $25,032,000 | 38.95% |
| Svennilson Peter | 18,017,932 | $286,665,000 | 23.39% |
| Aquilo Capital Management, LLC | 1,018,334 | $16,202,000 | 1.72% |
| Jasper Ridge Partners, L.P. | 308,750 | $4,912,000 | 0.28% |
| Samsara BioCapital, LLC | 36,451 | $580,000 | 0.16% |
| Rock Springs Capital Management LP | 360,454 | $5,735,000 | 0.15% |
| Point72 Asset Management, L.P. | 1,611,850 | $25,645,000 | 0.13% |
| Virtus ETF Advisers LLC | 14,880 | $237,000 | 0.12% |
| WELD CAPITAL MANAGEMENT LLC | 15,238 | $242,000 | 0.10% |